JP6345690B2 - 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用 - Google Patents

改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用 Download PDF

Info

Publication number
JP6345690B2
JP6345690B2 JP2015547567A JP2015547567A JP6345690B2 JP 6345690 B2 JP6345690 B2 JP 6345690B2 JP 2015547567 A JP2015547567 A JP 2015547567A JP 2015547567 A JP2015547567 A JP 2015547567A JP 6345690 B2 JP6345690 B2 JP 6345690B2
Authority
JP
Japan
Prior art keywords
axl
mer
tyro3
polypeptide
gas6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015547567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510309A (ja
JP2016510309A5 (OSRAM
Inventor
ジェイ． ジャシア，アマート
ジェイ． ジャシア，アマート
ブルーノ ランキン，エリン
ブルーノ ランキン，エリン
アール． コクラン，ジェニファー
アール． コクラン，ジェニファー
ジョーンズ，ダグラス
カリオリス，ミハリス
フウ，キャサリン
ミャオ，ユー
ハーシェンソン，スーザン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aravive Biologics Inc
Original Assignee
Aravive Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6345690(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aravive Biologics Inc filed Critical Aravive Biologics Inc
Publication of JP2016510309A publication Critical patent/JP2016510309A/ja
Publication of JP2016510309A5 publication Critical patent/JP2016510309A5/ja
Application granted granted Critical
Publication of JP6345690B2 publication Critical patent/JP6345690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015547567A 2012-12-14 2013-12-12 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用 Active JP6345690B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14
US61/737,276 2012-12-14
PCT/US2013/074786 WO2014093690A1 (en) 2012-12-14 2013-12-12 Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018098435A Division JP6832887B2 (ja) 2012-12-14 2018-05-23 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用

Publications (3)

Publication Number Publication Date
JP2016510309A JP2016510309A (ja) 2016-04-07
JP2016510309A5 JP2016510309A5 (OSRAM) 2017-02-02
JP6345690B2 true JP6345690B2 (ja) 2018-06-20

Family

ID=50934967

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015547567A Active JP6345690B2 (ja) 2012-12-14 2013-12-12 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用
JP2018098435A Expired - Fee Related JP6832887B2 (ja) 2012-12-14 2018-05-23 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018098435A Expired - Fee Related JP6832887B2 (ja) 2012-12-14 2018-05-23 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用

Country Status (11)

Country Link
US (3) US9822347B2 (OSRAM)
EP (2) EP3326622B1 (OSRAM)
JP (2) JP6345690B2 (OSRAM)
AU (3) AU2013359179B2 (OSRAM)
CA (1) CA2894539C (OSRAM)
DK (2) DK2931265T6 (OSRAM)
ES (2) ES2665323T7 (OSRAM)
FI (1) FI2931265T6 (OSRAM)
NO (1) NO3049208T3 (OSRAM)
PT (2) PT2931265T (OSRAM)
WO (1) WO2014093690A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
WO2011091305A2 (en) * 2010-01-22 2011-07-28 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
FI2931265T6 (fi) 2012-12-14 2023-05-23 Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa
CA2909669C (en) 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
WO2016100738A2 (en) * 2014-12-18 2016-06-23 Ruga Corporation Antifibrotic activity of gas6 inhibitor
MX2020007130A (es) * 2017-11-04 2021-02-15 Aravive Biologics Inc Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
CN118510543A (zh) * 2021-09-11 2024-08-16 艾拉维弗公司 使用axl诱饵受体作为一线疗法治疗局部晚期或转移性胰腺腺癌的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5538861A (en) 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030082767A1 (en) 1997-09-18 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
AU2003304180A1 (en) 2002-09-24 2005-01-04 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
CA2522984A1 (en) 2003-04-18 2004-10-28 Novartis Ag Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
EP1825005B1 (en) 2004-11-24 2015-07-15 The Regents of the University of Colorado, a body corporate Mer diagnostic and therapeutic agents
JP5219029B2 (ja) 2005-05-02 2013-06-26 東レ株式会社 食道ガン及び食道ガン転移診断のための組成物及び方法
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
WO2008128072A2 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
CA2692320A1 (en) 2007-07-02 2009-01-08 Wyeth Methods of treating bone disorders with modulators of axl
WO2010014755A1 (en) 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
EA201100947A1 (ru) * 2008-12-19 2012-02-28 Новартис Аг Растворимые полипептиды, предназначенные для применения при лечении аутоиммунных и воспалительных нарушений
EP2430050A1 (en) * 2009-05-11 2012-03-21 U3 Pharma GmbH Humanized axl antibodies
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
WO2011091305A2 (en) 2010-01-22 2011-07-28 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy
US10844106B2 (en) 2010-11-08 2020-11-24 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
FI2931265T6 (fi) 2012-12-14 2023-05-23 Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa
US20150315552A1 (en) 2012-12-14 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL Signaling in Primary Tumor Therapy
US20160266136A1 (en) * 2013-08-30 2016-09-15 The Board Of Trustees Of The Leland Stanford Junior University High-affinity binding to gas6
CA2909669C (en) * 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
WO2016100738A2 (en) * 2014-12-18 2016-06-23 Ruga Corporation Antifibrotic activity of gas6 inhibitor

Also Published As

Publication number Publication date
FI2931265T6 (fi) 2023-05-23
DK2931265T3 (en) 2018-04-16
EP2931265A1 (en) 2015-10-21
EP3326622B1 (en) 2021-01-20
US20220220458A1 (en) 2022-07-14
PT2931265T (pt) 2018-04-16
JP2016510309A (ja) 2016-04-07
AU2013359179A1 (en) 2015-07-02
HK1256071A1 (en) 2019-09-13
US20180030422A1 (en) 2018-02-01
WO2014093690A1 (en) 2014-06-19
ES2665323T3 (es) 2018-04-25
JP6832887B2 (ja) 2021-02-24
AU2019210662B2 (en) 2021-07-01
ES2862335T3 (es) 2021-10-07
DK3326622T3 (da) 2021-04-06
EP3326622A1 (en) 2018-05-30
AU2013359179B2 (en) 2017-10-05
ES2665323T7 (es) 2023-06-15
CA2894539A1 (en) 2014-06-19
JP2018154641A (ja) 2018-10-04
NO3049208T3 (OSRAM) 2018-04-14
EP2931265B3 (en) 2023-04-05
AU2019210662A1 (en) 2019-08-22
DK2931265T6 (da) 2023-05-01
EP2931265B1 (en) 2018-01-31
US11136563B2 (en) 2021-10-05
EP2931265A4 (en) 2016-08-31
US9822347B2 (en) 2017-11-21
US20150315553A1 (en) 2015-11-05
PT3326622T (pt) 2021-04-07
AU2017272193A1 (en) 2017-12-21
CA2894539C (en) 2021-09-28

Similar Documents

Publication Publication Date Title
JP6345690B2 (ja) 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用
JP5965322B2 (ja) 抗転移療法におけるａｘｌシグナル伝達の阻害
US20150315552A1 (en) Inhibition of AXL Signaling in Primary Tumor Therapy
US20130108644A1 (en) Inhibition of AXL Signaling in Anti-Metastatic Therapy
HK1256071B (en) Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy
HK1242355A1 (en) Inhibition of axl signaling in anti-metastatic therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161212

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20170426

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180424

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180523

R150 Certificate of patent or registration of utility model

Ref document number: 6345690

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250